Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
Although allogeneic transplantation can be curative for patients with sickle cell disease, the toxicity of conditioning regimens has precluded its use in adults with significant end-organ damage. Newer conditioning regimens have been developed that are less toxic and that may broaden the applicability of allogeneic transplantation in this disorder. We report two adults with end-stage sickle cell disease, who underwent allogeneic transplantation from an HLA-identical sibling donor after conditioning with fludarabine/melphalan and ATG. Both patients had been extensively transfused and one had multiple RBC antibodies. One of the patients also had end-stage renal disease, and was dialysis dependent. Engraftment occurred promptly in both patients. Both achieved 100% donor chimerism and both were free of pain crises after transplant. The first patient died of a respiratory failure related to chronic graft-versus-host disease (GVHD) on day 335 after transplantation. The second patient developed severe gastro-intestinal GVHD and TTP and died on day 147 after transplantation. Conditioning with fludarabine/melphalan and ATG followed by allogeneic stem cell transplantation resulted in prompt and reliable engraftment in adults with end-stage sickle cell disease. The incidence of severe GVHD was unacceptably high and may be related to the ethnicity of the patients or to the inflammatory state associated with pre-existing sickle cell disease.
van Besien
K
K
Section of Hematology/Oncology University of Illinois College of Medicine, Chicago 60612, USA.
Bartholomew
A
A
Stock
W
W
Peace
D
D
Devine
S
S
Sher
D
D
Sosman
J
J
Chen
Y H
YH
Koshy
M
M
Hoffman
R
R
D000328:Adult; D000755:Anemia, Sickle Cell / Q000628:therapy*; D017809:Fatal Outcome; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000633:toxicity; D008875:Middle Aged; D009679:Nuclear Family; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods / Q000592:standards; D014184:Transplantation, Homologous / Q000379:methods; D014740:Vidarabine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000633:toxicity
D007166:Immunosuppressive Agents; D014740:Vidarabine; C024352:fludarabine